US Equities insigtX

Clarity AD CSF Subgroup: Lecanemab Efficacy Data in α-Synuclein Co-Pathology Announced

Tokyo and Cambridge, MA, November 19, 2026 -- Eisai Co., Ltd. and Biogen Inc. announced today the presentation of results from an analysis of lecanemab-irmb treatment in the…

Published
Market
US Equities
Source
insigtX

Tokyo and Cambridge, MA, November 19, 2026 -- Eisai Co., Ltd. and Biogen Inc. announced today the presentation of results from an analysis of lecanemab-irmb treatment in the context of α-synuclein co-pathology* from the Clarity AD cerebrospinal fluid (CSF) substudy in early Alzheimer's disease (AD), at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, held virtually and in Boston. In AD, α-Syn co-pathology may coexist with amyloid beta and tau pathologies. α-Syn co-pathology may contribute to clinical heterogeneity and disease progression in AD, but its clinical relevance in early AD patients receiving amyloid-targeting therapy remains unclear. In Clarity AD, lecanemab demonstrated statistically significant slowing of clinical decline in participants with early AD. This post-hoc analysis evaluated the prevalence of α-Syn co-pathology, clinical features associated with α-Syn co-pathology, and examined changes in clinical assessment scores over time between lecanemab and placebo groups in the overall α-Syn-evaluable population and in the α-Syn-positive group. These findings were presented in an oral presentation titled "Lecanemab Treatment and α-Synuclein Co-Pathology in the Clarity AD CSF Substudy."

Overview of the Clarity AD CSF Substudy Analysis

A total of 623 CSF samples collected from Clarity AD participants at screening or baseline were evaluated using the Amprion SYNTap seed amplification technology**. α-Syn status was determined based on detection of α-Syn seeds in CSF and used as an indicator of α-Syn co-pathology in the brain. Among amyloid-positive participants who were randomized to lecanemab or placebo and had α-Syn results, 400 were included in the α-Syn-evaluable population.

Key Findings

The prevalence of α-Syn pathology was higher in Aβ+ participants than in Aβ- participants. Analysis of 623 CSF samples showed that the prevalence of α-Syn pathology was higher in the Aβ+ group compared to the amyloid-negative group.

α-Syn+ participants had higher baseline amyloid burden, and α-Syn co-pathology was associated with faster progression in early AD. Among randomized participants with evaluable baseline amyloid PET assessments, the mean amyloid burden in the α-Syn+ group was 86 Centiloids***, compared to 67 CL in the α-Syn-negative group. The difference between groups was statistically significant. α-Syn+ was also associated with faster clinical decline over 18 months.

Lecanemab slowed clinical decline in both the overall α-Syn-evaluable population and the α-Syn+ group. In this analysis, compared with placebo, lecanemab showed slowing of clinical decline at 18 months in the overall α-Syn-evaluable population, which was similar to that observed in the overall Clarity AD population. In an exploratory post-hoc analysis limited to the α-Syn+ group, lecanemab also showed slowing of clinical decline at 18 months compared with placebo. Specifically, as measured by CDR-SB, the slowing of decline compared with placebo was 27% in the overall Clarity AD population, 26% in the overall α-Syn-evaluable population, and 41% in the α-Syn+ group. As measured by ADAS-Cog14, the slowing was 26%, 45%, and 43%, respectively; and as measured by ADCS MCI-ADL, the slowing was 37%, 30%, and 43%, respectively.**** These findings suggest that lecanemab provides clinical benefit for individuals with α-Syn co-pathology.

Eisai serves as the lead for lecanemab's global development and regulatory submissions, with both companies co-commercializing and co-promoting the product, with Eisai having final decision-making authority.

* α-synuclein is a protein abundant in nerve cells that plays a role in synaptic signaling. Structurally abnormal α-Syn aggregates and forms deposits called Lewy bodies. Lewy bodies are pathological hallmarks of Parkinson's disease and dementia with Lewy bodies. In AD, α-Syn-related pathology can coexist with amyloid and tau-related pathology in the same individual. This is referred to as α-Syn co-pathology.
** The Amprion SYNTap seed amplification technology detects structurally abnormal α-Syn aggregates in samples by using them as seeds and amplifying their reaction in vitro.
*** The Centiloid scale standardizes brain amyloid burden measured by amyloid PET; higher values indicate greater amyloid burden. The scale is anchored at 0 CL and 100 CL. The mean baseline value in Clarity AD was approximately 78 CL. Plaque-negative was defined as conversion to amyloid PET-negative status.
**** CDR-SB assesses overall clinical status, including cognition and daily function; lower scores indicate better status. ADAS-Cog14 assesses cognitive function; lower scores indicate better status. ADCS MCI-ADL assesses daily function and independence in patients with mild cognitive impairment.

Notes to Editors

1. About lecanemab
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. Lecanemab has been approved in 53 countries and regions, including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following an initial phase of once-every-two-weeks treatment for 18 months, a once-every-four-weeks intravenous maintenance dosing regimen has been approved in 9 countries, including the United States, China, and the United Kingdom, and applications have been submitted in 11 countries and regions. The U.S. FDA approved Eisai's Biologics License Application for the LEQEMBI IQLIK subcutaneous maintenance dose in August 2025. For subcutaneous initiation therapy, approvals were granted in the United States in July 2026 and in China and Japan in September 2026, with applications under review in 4 countries. Since July 2020, a Phase 3 clinical study for individuals with preclinical AD has been ongoing. AHEAD 3-45 is being conducted as a public-private partnership with the Alzheimer's Clinical Trial Consortium, which provides infrastructure for academic clinical trials in AD and related dementias in the United States, funded by the National Institute on Aging, part of the U.S. National Institutes of Health, Eisai, and Biogen. Since January 2022, the Tau NexGen clinical study for dominantly inherited AD has been ongoing, conducted by the Dominantly Inherited Alzheimer Network Trials Unit led by Washington University School of Medicine in St. Louis, with lecanemab as the background anti-amyloid therapy.

2. About protofibrils
Protofibrils are believed to contribute to the brain damage that occurs in AD and are considered the most toxic form of soluble Aβ, playing a major role in the cognitive decline associated with this progressive, debilitating disease.1 Protofibrils cause damage to neurons in the brain, which in turn may negatively impact cognitive function through multiple mechanisms, not only increasing the formation of insoluble Aβ plaques but also directly damaging cell membranes and the connections that transmit signals between nerve cells or between nerve cells and other cells. It is believed that reducing protofibrils may halt the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2

3. About the collaboration between Eisai and Biogen in AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD therapies since 2014. Eisai serves as the lead for LEQEMBI's global development and regulatory submissions, with both companies co-commercializing and co-promoting the product, with Eisai having final decision-making authority.

4. About the collaboration between Eisai and BioArctic in AD
Since 2005, Eisai and BioArctic have had a long-term collaboration on the development and commercialization of AD therapies. Under an agreement reached with BioArctic in December 2007, Eisai obtained the global rights to research, develop, manufacture, and market lecanemab for the treatment of AD. An agreement for the development and commercialization of the antibody lecanemab backup was signed in May 2015.

5. About Eisai Co., Ltd.
Eisai's corporate concept is "to put patients and people in their daily lives first and increase the benefits that healthcare provides." Under this concept, also known as the human health care (hhc) concept, we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites, and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus on our strategic areas: neurology and oncology. Furthermore, through various activities with global partners, we demonstrate our commitment to eliminating neglected tropical diseases, a specific target of the United Nations Sustainable Development Goals. For more information about Eisai, please visit www.eisai.com and connect with us on X, LinkedIn, and Facebook. This website and social media channels are intended for audiences outside of the UK and Europe. For UK and European audiences, please visit www.eisai.eu and Eisai EMEA LinkedIn.

6. About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines that transform patients' lives and create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment, to deliver long-term growth. The company regularly posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor Statement

This news release contains forward-looking statements, including statements about the potential clinical effects of LEQEMBI; the potential benefits, safety, and efficacy of LEQEMBI; the potential for the LEQEMBI autoinjector to increase flexibility in treatment options, reduce healthcare resource use, and reduce the time and burden required for clinical visits; potential regulatory discussions, submissions, and approvals and their timing; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangement with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by words such as "aim," "anticipate," "assume," "believe," "consider," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would," and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs ultimately result in commercialization of a product. Results from early clinical trials may not be representative of full results or results from later or larger-scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve significant risks and uncertainties, may be based on inaccurate assumptions, and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. By their nature, we cannot guarantee that any of the outcomes expressed in these forward-looking statements will be realized, in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are beyond our control, and could cause future events or results to differ materially from those stated or implied in this document, including, but not limited to: uncertainty of success in the development, licensing, or acquisition of other product candidates or additional indications for existing products; expectations, plans, and projections relating to approvals of products, approvals of additional indications for existing products, sales, pricing, growth, reimbursement, and launches of marketed products and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategy and growth initiatives; the risk that positive results in clinical trials may not be replicated in subsequent or confirmatory trials, or that success in early clinical trials may not predict results from later or larger-scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, the possibility of unexpected concerns that may arise from additional data or analysis obtained during clinical trials, the possibility that regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use of our products, or product liability claims; and any other risks and uncertainties described in our other reports filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release and are based on information and estimates available to us at this time. If known or unknown risks or uncertainties materialize, or if underlying assumptions prove inaccurate, actual results could differ materially from past results and from anticipated, estimated, or projected results. Investors are cautioned not to place undue reliance on forward-looking statements. A further list and description of risks, uncertainties, and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in our subsequent reports on Form 8-K. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, changes in circumstances, or otherwise, except as required by law.

Digital Media Disclosure

We use, and intend to continue to use, our investor relations website, the Biogen LinkedIn account, and the Biogen X account (as a means of disclosing material non-public information to the public in a broad, non-exclusionary manner, including for the purposes of the U.S. Securities and Exchange Commission's Regulation Fair Disclosure. Accordingly, investors should monitor our investor relations website and these social media channels, in addition to following our press releases, U.S. Securities and Exchange Commission filings, public conference calls, and webcasts, as information posted on these channels could be material to investors.

References

Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z
Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21:952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

Original: https://www.globenewswire.com/news-release/2026/11/19/3407044/0/en/clarity-ad-csf-substudy-findings-on-lecanemab-treatment-and-%CE%B1-synuclein-co-pathology-presented-at-ctad-2026.html

insigtX content is informational and educational, not investment advice.